Skip to main content

Peer Review reports

From: Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial

Original Submission
7 Dec 2018 Submitted Original manuscript
24 Apr 2019 Reviewed Reviewer Report - Rani Jayswal
6 May 2019 Reviewed Reviewer Report - V Rocha
20 May 2019 Author responded Author comments - Laila König
Resubmission - Version 2
20 May 2019 Submitted Manuscript version 2
30 May 2019 Reviewed Reviewer Report - Rani Jayswal
23 Jul 2019 Reviewed Reviewer Report - V Rocha
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
24 Jul 2019 Editorially accepted
30 Aug 2019 Article published 10.1186/s13063-019-3614-y

You can find further information about peer review here.

Back to article page